Benzinga | Aug 5, 2021 05:48PM EDT

CytomX Therapeutics Q2 EPS $(0.30) Beats $(0.32) Estimate, Sales $16.00M Miss $16.86M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 11.76 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $16.00 million which missed the analyst consensus estimate of $16.86 million by 5.10 percent. This is a 3.66 percent decrease over sales of $16.61 million the same period last year.